AES Corp/ US00130H1059 /
2024-11-12 10:10:00 PM | Chg. -0.44 | Volume | Bid10:23:07 PM | Ask10:23:07 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
13.45USD | -3.17% | 14.5 mill. Turnover: 171.56 mill. |
13.33Bid Size: 500 | 13.74Ask Size: 500 | 9.56 bill.USD | 4.98% | 36.35 |
Newsfile Corp
2:30 PM
Lion One Commences Development of High-Grade Roscoelite Zone at Tuvatu Gold Mine in Fiji
Newsfile Corp
10-29
Perseverance Metals Announces New Critical Mineral Discoveries from the Lac Gayot Nickel-Copper-PGE ...
Newsfile Corp
09-19
Perseverance Metals Discovers New Nickel Zone, Yields 1.82% NiEq over 5.1 Meters at Lac Gayot Projec...
Newsfile Corp
09-17
Endurance Announces First 2024 Drill Results At The Reliance Gold Project, BC; Initial Six Holes Exp...
GlobeNewswire
08-30
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizu...
GlobeNewswire
08-28
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Port...
Newsfile Corp
08-26
ALX Resources Corp. Completes Prospecting and Sampling Programs at the Cannon Copper Project, Ontari...
GlobeNewswire
08-22
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderat...
Newsfile Corp
08-20
Appia Confirms Outstanding Desorption Results From Its Ionic Adsorption Clay Targets Maia, Electra, ...
GlobeNewswire
08-15
Great Place To Work® Announces the 2024 Best Workplaces in Latin America Representing 3.8 Million Em...
GlobeNewswire
08-14
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic...
GlobeNewswire
08-14
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-12
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
GlobeNewswire
08-12
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at...
GlobeNewswire
08-08
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3...